CD8A and neoplasm: Most cell therapy products are a combination of CD8 and CD4 T cells, and in terms of anti‐tumor killing dynamics, CD4 CAR‐T cells are slower, less prone to exhaustion, and are more persistent following antigen exposure compared to CD8 T cells.